Serum Institute's HPV Vaccine Cervavac Gets WHO Prequalification
Serum Institute of India's recombinant Quadrivalent HPV vaccine, Cervavac, has received WHO prequalification. Targeting HPV types 6, 11, 16, and 18, it is for girls and boys aged 9 to 26. This allows UN agencies to procure it. Developed with DBT, BIRAC, WHO-IARC, and the Gates Foundation, Cervavac is Serum Institute's 32nd WHO prequalified product.
Hindu Health··Hyderabad




